Co-Authors
This is a "connection" page, showing publications co-authored by Lawrence Corey and Peter Gilbert.
Connection Strength
2.304
-
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis. 2017 Jan; 9(1).
Score: 0.719
-
Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. Clin Infect Dis. 2021 10 20; 73(8):1540-1544.
Score: 0.244
-
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Ann Intern Med. 2021 02; 174(2):221-228.
Score: 0.227
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0.211
-
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS One. 2017; 12(11):e0185959.
Score: 0.186
-
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One. 2017; 12(5):e0176428.
Score: 0.179
-
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs. 2017 07; 9(5):792-800.
Score: 0.178
-
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Ann Intern Med. 2021 08; 174(8):1118-1125.
Score: 0.059
-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
Score: 0.058
-
Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020 11 04; 12(568).
Score: 0.057
-
Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. AIDS Res Hum Retroviruses. 2018 08; 34(8):645-656.
Score: 0.048
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0.048
-
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. Clin Vaccine Immunol. 2017 Nov; 24(11).
Score: 0.046
-
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis. 2017 05 01; 215(9):1376-1385.
Score: 0.045